Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Identification of a Novel and Efficacious Oral Proteasome Inhibitor As a Potential Clinical Development Candidate

Kwang-Ai Won, PhD, Byung Gyu Kim, Cheol-Kyu Jung, Eok Park, Eunbok Baek, Jonghoon Park, Seung-Wan Kang, Tae Hun Kim, Youngjoo Jung

Blood (2014) 124 (21): 4808.

https://doi.org/10.1182/blood.V124.21.4808.4808

Published: 2014

Journal Articles

Long-Term Assessment of Dasatinib-Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukemia

Jee Hyun Kong, Dr, Young-Woo Jeon, Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Yun Jeong Oh, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Suk Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 5535.

https://doi.org/10.1182/blood.V124.21.5535.5535

Published: 2014

Journal Articles

Six-Year Follow-Up Of Dasatinib-Related Pulmonary Arterial Hypertension (PAH) For Chronic Myeloid Leukemia In Single Center

Young-Woo Jeon, M.D., Sung-Eun Lee, M.D., Soo-Hyun Kim, Soo-Young Choi, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 4017.

https://doi.org/10.1182/blood.V122.21.4017.4017

Published: 2013

Journal Articles

Plasma Imatinib Trough Level Is a Predictor For 3-Month Early Molecular Response In New CP CML Patients

Sung-Eun Lee, M.D., Soo Young Choi, Soo-Hyun Kim, Yun Jeong Oh, Jin-Eok Park, Eun-Jung Jang, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 2716.

https://doi.org/10.1182/blood.V122.21.2716.2716

Published: 2013

Journal Articles

Kinetics Of Low-Level Mutant Clones Detected By Subcloning and Sequencing In Tyrosine Kinase Inhibitor Resistant CML

Soo-Hyun Kim, Soo Young Choi, Sung-Eun Lee, M.D., Yun Jeong Oh, Jin-Eok Park, Hae Lyun Yoo, Hye-Rim Jeon, Eun-Jung Jang, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 2720.

https://doi.org/10.1182/blood.V122.21.2720.2720

Published: 2013

Journal Articles

Predictive Factors For An Achievement Of 6-Month Early Molecular Response In New CP CML Patients Treated With Imatinib

Sung-Eun Lee, M.D., Soo Young Choi, Soo-Hyun Kim, Yun Jeong Oh, Jin-Eok Park, Eun-Jung Jang, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 5160.

https://doi.org/10.1182/blood.V122.21.5160.5160

Published: 2013

Journal Articles

Peripheral Arterial Occlusive Disease (PAOD) In Chronic Phase Chronic Myeloid Leukemia Patients Treated With Nilotinib

Young-Woo Jeon, M.D., Sung-Eun Lee, M.D., Soo-Young Choi, Soo-Hyun Kim, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 4018.

https://doi.org/10.1182/blood.V122.21.4018.4018

Published: 2013

Journal Articles

Dynamics and Characteristics of BCR-ABL1 Multiple Mutations in Tyrosine Kinase Inhibitor Resistant CML

Soo-Hyun Kim, Soo Young Choi, Sung-Eun Lee, Ju-Hee Bang, Ji-Young Byeun, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Saengsuree Jootar, Dong-Wook Kim

Blood (2012) 120 (21): 1677.

https://doi.org/10.1182/blood.V120.21.1677.1677

Published: 2012

Journal Articles

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Blood (2012) 120 (21): 3775.

https://doi.org/10.1182/blood.V120.21.3775.3775

Published: 2012

Journal Articles

Comparison of Sokal, Hasford and EUTOS Scores in Terms of Long-Term Treatment Outcome According to the Risks in Each Prognostic Model: A Single Center Data Analyzed in 255 Early Chronic Phase Chronic Myeloid Leukemia Patients Treated with Frontline Imatinib Mesylate.

Seung-Ah Yahng, Eun-Jung Jang, Soo Young Choi, Yun-Jung Oh, Ju-Hee Bang, Jin-Eok Park, Hye-Lim Jeon, Sung-Eun Lee, Soo-Hyun Kim, Ji-Young Byun, Dong-Wook Kim

Blood (2012) 120 (21): 2794.

https://doi.org/10.1182/blood.V120.21.2794.2794

Published: 2012

Journal Articles

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management

Susan Branford, David T. Yeung, Jodi A. Prime, Soo-Young Choi, Ju-hee Bang, Jin Eok Park, Dong-Wook Kim, David M. Ross, Timothy P. Hughes

Blood (2012) 119 (18): 4264–4271.

https://doi.org/10.1182/blood-2011-11-393041

Published: 2012

Includes: Supplemental data

NARROW

Identification of a Novel and Efficacious Oral Proteasome Inhibitor As a Potential Clinical Development Candidate

Long-Term Assessment of Dasatinib-Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukemia

Six-Year Follow-Up Of Dasatinib-Related Pulmonary Arterial Hypertension (PAH) For Chronic Myeloid Leukemia In Single Center

Plasma Imatinib Trough Level Is a Predictor For 3-Month Early Molecular Response In New CP CML Patients

Kinetics Of Low-Level Mutant Clones Detected By Subcloning and Sequencing In Tyrosine Kinase Inhibitor Resistant CML

Predictive Factors For An Achievement Of 6-Month Early Molecular Response In New CP CML Patients Treated With Imatinib

Peripheral Arterial Occlusive Disease (PAOD) In Chronic Phase Chronic Myeloid Leukemia Patients Treated With Nilotinib

Dynamics and Characteristics of BCR-ABL1 Multiple Mutations in Tyrosine Kinase Inhibitor Resistant CML

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Comparison of Sokal, Hasford and EUTOS Scores in Terms of Long-Term Treatment Outcome According to the Risks in Each Prognostic Model: A Single Center Data Analyzed in 255 Early Chronic Phase Chronic Myeloid Leukemia Patients Treated with Frontline Imatinib Mesylate.

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only